AtriCure Tops Q3 Revenue Estimates, Forecasts 109% FY2026 Earnings Growth
AtriCure reported a third-quarter 2025 adjusted loss of $0.01 per share, narrower by 90.9% from expectations, while revenue of $134.3 million exceeded consensus by 2.1%. The company projects a 109.1% earnings growth rate for fiscal 2026, far outpacing the 15.8% industry average.
1. Q3 2025 Financial Performance
AtriCure delivered third-quarter 2025 results with an adjusted loss of $0.01 per share, a 90.9% improvement over consensus, and revenue of $134.3 million, 2.1% above analyst estimates. The outperforming top line reflects steady demand for the company’s surgical ablation devices and related procedural tools.
2. 2026 Earnings Outlook
Management projects a 109.1% earnings growth rate for fiscal 2026, driven by anticipated volume growth, expanded procedure adoption and potential margin enhancements from operational leverage. This outlook contrasts sharply with the broader medical device industry’s 15.8% expected earnings rise.
3. Market Position and Peer Comparison
AtriCure holds a Zacks Rank #1 in the medical device sector, highlighting its relative strength versus peers. The company’s robust growth forecast positions it as one of the fastest-growing players in electrophysiology and cardiac surgical markets, underpinned by a focused product portfolio and innovation pipeline.